Founded in 2005, biopharmaceutical company CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) is focused on developing small molecules for the acute treatment of migraine headaches. The company’s lead product candidates are oral lasmiditan, an oral tablet for the acute treatment of migraine headaches in adults; and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. For more information, visit the company’s website at www.colucid.com.